

Supplemental documents (supplemental tables 1-3)

Table S1. Demographics and Pre-treatment Characteristics of HCT Recipients

Protocol	UPN	HCT	HLA-match	Time ^A	Age	ExN ^B	CNS	LN ^C	≥ 3 sites	# Rx ^D	Doses of Ritux ^E	Response to Ritux	Prior RT	Response to RT	Prior Chemo	Chemo, Specify	Other EBV Therapy	Response to Other Therapy	Response to EBV-CTLs
95-024	5630	CBU	5/6	34	8.0	Y	N	A/B	Y	2	5	POD	N	n/a	Y	Methylpred Cyclophos	N	n/a	POD
95-024	5634	PBSCT	9/10	68	17.4	Y	Y	A/B	Y	3	1	PR ->POD	N	n/a	Y	ANHL0221	tonsillectomy	local control	POD
11-130	5627	cBMT	8/10	14	19.0	Y	N	A/B	Y	2	4	SD	N	n/a	N	n/a	tonsillectomy	local control	CR
11-130	4234	TCD PBSCT	10/10	37	65.5	N	N	A/B	Y	1	4	PR	N	n/a	N	n/a	N	n/a	CR
11-130	4835	TCD PBSCT	9/10	40	52.0	Y	N	A/B	Y	2	4	POD	N	n/a	N	n/a	tonsillectomy	local control	POD
11-130	4513	TCD PBSCT	10/10	32	63.4	Y	N	N	N	1	4	PR	N	n/a	N	n/a	N	n/a	PR
11-130	5605	TCD BMT	9/10	13	11.0	N	N	A/B	N	1	5	SD	N	n/a	N	n/a	N	n/a	CR
11-130	5613	DUBCT	5/6; 4/6	71	68.4	N	N	B	N	2	8	CR ->REL	N	n/a	Y	Brentuximab	N	n/a	POD
11-130	5601	TCD PBSCT	10/10	54	74.1	Y	N	A	Y	1	5	POD	N	n/a	N	n/a	N	n/a	POD
11-130	5431	TCD PBSCT	8/10	17	23.7	N	N	A	N	1	4	PR	N	n/a	N	n/a	N	n/a	CR
11-130	5625	cBMT	8/10	39	28.4	Y	N	A/B	Y	1	6	PR -> POD	N	n/a	N	n/a	N	n/a	POD
11-130	5619	TCD PBSCT	5/10	8	19.7	N	N	A/B	N	1	4	POD	N	n/a	N	n/a	N	n/a	CR
95-024	5632	CBU	4/6	11	11.4	Y	N	A/B	Y	2	5	POD	N	n/a	Y	HU	N	n/a	CR
95-024	5633	PBSCT	10/10	37	63.1	Y	N	A/B	Y	1	6	POD	N	n/a	N	n/a	N	n/a	CR
11-130	5558	cBMT	10/10	8	28.2	Y	N	A/B	Y	1	2	SD	N	n/a	N	n/a	N	n/a	CR
11-130	5626	cBMT	10/10	43	19.4	Y	N	N	Y	1	5	POD	N	n/a	N	n/a	N	n/a	N/E
95-024	5628 ^f	CBU	5/6	169	7.7	Y	N	N	N	2	>14	CR -> POD	Y	local control	N	n/a	N	n/a	POD
95-024	3520 ^f	TCD PBSCT	10/10	6	62.4	Y	N	A/B	Y	1	1	N/A	N	n/a	N	n/a	N	n/a	CR
11-130	5597	DUBCT	4/6; 4/6	14	21.5	Y	N	A/B	Y	1	2	POD	N	n/a	N	n/a	N	n/a	CR
11-130	5592	PBSCT	10/10	17	52.6	N	N	A	N	1	3	POD	N	n/a	N	n/a	N	n/a	CR

95-024	3886	TCD PBSCT	10/10	7	36.0	Y	N	A/B	Y	1	5	CR -> REL	N	n/a	N	n/a	N	n/a	CR
11-130	4286	TCD PBSCT	9/10	9	20.4	Y	N	A/B	Y	1	3	POD	N	n/a	N	n/a	N	n/a	POD
11-130	5602	DUBCT	5/6; 4/6	141	59.2	Y	N	N	N	3	4	CR ->REL	Y	PR	Y	R-CHOP	N	n/a	CR
11-130	5616	cBMT	10/10	41	17.7	Y	Y	A/B	Y	1	4	SD	N	n/a	N	n/a	N	n/a	CR
95-024	5631	PBSCT	8/8	42	70.4	Y	N	N	N	1	5	POD	N	n/a	N	n/a	N	n/a	CR
95-024	5629 ^f	CBU	4/6	104	10.0	Y	Y	N	N	3	8	PR	Y	PR	Y	HU	N	n/a	CR
11-130	5609	DUBCT	4/6; 4/6	53	66.7	Y	N	A/B	Y	2	4	POD	N	n/a	Y	R-EPOCH	N	n/a	POD
11-130	5593	TCD PBSCT	8/8 (9/10)	11	5.1	N	N	A/B	N	4	2	POD	Y	POD	N	n/a	boost; tonsillectomy	local control	PR
11-130	5603	cBMT	9/10	57	15.7	Y	Y	N	Y	1	7	SD	N	n/a	N	n/a	N	n/a	PR
11-130	5091	DUBCT CBU	5/6, 5/6 4/6	11	54.7	Y	N	B	Y	1	3	SD	N	n/a	N	n/a	N	n/a	CR
11-130	5622	CBU	3/6	24	16.7	N	Y	N	N	1	4	SD	N	n/a	N	n/a	N	n/a	CR
95-024	3603 ^f	TCD PBSCT	7/10	43	5.6	Y	N	B	Y	2	6	POD	N	n/a	N	n/a	1* EBV CTLs	POD	CR
11-130	4032	cBMT	9/10	19	72.7	Y	N	N	N	1	4	POD	N	n/a	N	n/a	N	n/a	POD

- A. Time from proximate diagnosis of EBV-LPD to start of EBV-CTLs
- B. Extranodal involvement; Y=Yes, N=No
- C. Involvement of Lymph Nodes Above (A) or Below (B) the diaphragm
- D. Number of prior therapies
- E. Number of doses of Rituximab (some given with chemotherapy)
- F. Patient previously reported (17, 30)

Table S2. Demographics and Pre-Treatment Characteristics of SOT Recipients

Protocol	UPN	Age at SOT	Organ	Prior Rejection ^A	Time ^B	ExN ^C	CNS	LN ^D	≥ 3 sites	Prior RT	Prior CHEMO	Disease Status at Start of EBV-CTLs	Response to EBV-CTLs
11-130	5618	2.5	HEART	Y	34	Y	Y	a/b	Y	N	Y	Recurrent	POD
95-024	5639	2.7	SMALL BOWEL	Y	221	Y	N	a/b	Y	N	Y	Recurrent	SD
11-130	5598	1.8	RENAL	Y	448	N	Y	N	N	N	Y	Residual	CR
11-130	5624	1.7	HEART	Y	99	Y	N	a/b	Y	N	Y	Recurrent	POD
95-024	5637	3.4	RENAL	N	184	Y	N	a/b	Y	Y	Y	Recurrent	POD
11-130	5606	24.7	RENAL	N	36	N	Y	N	N	Y	N	Residual	PR
11-130	5744	35.0	LUNG	Y	142	Y	N	a/b	Y	N	Y	Recurrent	POD
11-130	5599	10.7	LIVER	Y	160	N	Y	N	N	Y	Y	Residual	PR
11-130	5604	18.1	RENAL	N	382	Y	N	b	N	Y	Y	POD	POD
11-130	5620	75.2	RENAL	N	83	N	Y	N	N	N	N	POD	CR
95-024	5640	0.7	HEART	Y	21	Y	N	a/b	Y	N	Y	Recurrent	PR
95-024	5638	42.2	LIVER	Y	224	N	N	a	N	N	Y	Recurrent	PR
11-130	5595	18.0	HEART/LIVER	Y	232	N	Y	N	N	Y	Y	POD	PR

- A. Episodes of prior solid organ rejection Yes (Y) or No (N)
- B. Time from proximate diagnosis of EBV-LPD to start of EBV-CTLs
- C. Extranodal involvement; Y=Yes, N=No
- D. Involvement of Lymph Nodes Above (A) or Below (B) the diaphragm

Table S3. Histology, Clonality, Origin and Proliferative index of the Post-Transplant EBV+ Lymphomas

UPN	Protocol	Transplant	Pathology	clonality	Origin	Proliferative Index
3520	95-024	HCT	lymphoid hyperplasia	unknown	unknown	unknown
3603	95-024	HCT	monomorphic DLBCL	clonal	host	80%
3886	95-024	HCT	monomorphic DLBCL	unknown	donor	60-70%
4032	11-130	HCT	monomorphic DLBCL	unknown	unknown	80-90%
4234	11-130	HCT	monomorphic DLBCL	unknown	unknown	90%
4286	11-130	HCT	monomorphic DLBCL	not clonal	donor	90%
4513	11-130	HCT	monomorphic DLBCL	unknown	unknown	80%
4835	11-130	HCT	monomorphic DLBCL	clonal	donor	70%
5431	11-130	HCT	mononucleosis like PTLD	oligoclonal	unknown	40%
5592	11-130	HCT	monomorphic DLBCL	clonal	donor	> 90%
5593	11-130	HCT	monomorphic DLBCL w/plasmacytoid	clonal	unknown	70-90%
5597	11-130	HCT	monomorphic DLBCL	not clonal	host	90%
5601	11-130	HCT	polymorphic	clonal	unknown	80%
5602	11-130	HCT	monomorphic DLBCL	unknown	unknown	unknown
5603	11-130	HCT	monomorphic DLBCL	unknown	donor	70%
5605	11-130	HCT	monomorphic DLBCL	clonal	unknown	90%
5609	11-130	HCT	monomorphic DLBCL	clonal	donor	unknown
5613	11-130	HCT	Hodgkin Like	n/a	unknown	>50%
5616	11-130	HCT	polymorphic DLBCL w/plasmacytoid	not clonal	unknown	90%
5622	11-130	HCT	monomorphic DLBCL	not clonal	donor	90%
5625	11-130	HCT	monomorphic DLBCL	clonal	donor	>90%
5626	11-130	HCT	monomorphic DLBCL	clonal	unknown	unknown
5627	11-130	HCT	monomorphic DLBCL	clonal	unknown	60-70%
5628	95-024	HCT	monomorphic DLBCL	clonal	donor	>90%
5629	95-024	HCT	monomorphic DLBCL	clonal	donor	>90%
5630	95-024	HCT	monomorphic DLBCL	clonal	donor	80%
5631	95-024	HCT	monomorphic DLBCL	unknown	unknown	unknown
5632	95-024	HCT	monomorphic DLBCL	clonal	unknown	unknown
5633	95-024	HCT	polymorphic DLBCL w/ plasmacytoid	clonal	unknown	unknown
5634	95-024	HCT	monomorphic DLBCL	clonal	donor	70%
5595	11-130	SOT	monomorphic DLBCL	not clonal	host	unknown
5598	11-130	SOT	polymorphic w/ Hodgkin-like	n/a	host	50-60%
5599	11-130	SOT	monomorphic DLBCL	unknown	host	unknown
5604	11-130	SOT	monomorphic DLBCL w/ plasmacytoid	unknown	unknown	80%
5606	11-130	SOT	monomorphic DLBCL	unknown	host	30-50%
5618	11-130	SOT	monomorphic DLBCL	not clonal	unknown	> 50%
5620	11-130	SOT	monomorphic DLBCL	clonal	host	unknown
5624	11-130	SOT	monomorphic DLBCL	clonal	unknown	70%
5637	95-024	SOT	polymorphic DLBCL	not clonal	unknown	>90%
5638	95-024	SOT	polymorphic w/ plasmacytoid	unknown	unknown	unknown
5639	95-024	SOT	polymorphic DLBCL	clonal	host	80% (MIB-1)
5640	95-024	SOT	polymorphic DLBCL	clonal	host	unknown
5744	11-130	SOT	monomorphic DLBCL	clonal	unknown	50-80%